腔道介入治疗仪对盆腔炎症包块患者细胞因子的影响

doi:10.20047/j.issn1673-7210.2022.27.23

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (674 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of intracavitary interventional therapy instrument on cytokines in patients with pelvic inflammatory mass. Methods A total of 130 patients with pelvic inflammatory mass admitted to the Department of Gynecology, Cangzhou People’s Hospital of Hebei Province from October 2018 to June 2020 were selected as the research objects, according to the random number table method, they were divided into medication group and treatment instrument group, with 65 ceses in each group. The medication group was treated with Metronidazole combined with Doxycycline, while the treatment instrument group was treated with luminal interventional therapy instrument. The levels of cytokines (granulocyte-macrophage colony-stimulating factor [GM-CSF], C-reactive protein [CRP], tumor necrosis factor-α [TNF-α], and interleukin-6 [IL-6]), hemorheology, pelvic mass diameter, and pain degree were observed before and after treatment, the clinical efficacy and adverse reactions of the two groups were statistically analyzed. Results After treatment, the levels of GM-CSF, CRP, TNF-α, and IL-6 in the two groups were lower than those before treatment, and the study group was lower than the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the hemorheological indexes of the two groups were lower than those before treatment, and the hemorheological indexes of the study group were lower than those of the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the pelvic mass diameter and visual analogue scales score of the two groups were lower than those before treatment, and the study group was lower than the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the clinical effect of the therapeutic apparatus group was better than that of the drug group, and the difference was statistically significant (P ＜ 0.05). There was no significant difference in adverse reactions between the two groups (P ＞ 0.05). Conclusion The treatment of patients with pelvic inflammatory mass by cavity interventional therapy device is effective and can reduce cytokines, which is worthy of clinical promotion.

Key words： Luminal interventional therapy apparatus Pelvic inflammatory mass Cytokines Blood rheology

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Zaihong YU Xianbo ZHAO Lixia LI Chengcheng ZHU Ping

Cite this article:

ZHENG Zaihong YU Xianbo ZHAO Lixia LI Chengcheng ZHU Ping. Effect of intracavitary interventional therapy instrument on cytokines in patients with pelvic inflammatory mass[J]. 中国医药导报, 2022, 19(27): 101-105.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.27.23 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I27/101

[1] Ravel J，Moreno I，Simón C. Bacterial vaginosis and its association withinfertility，endometritis，and pelvic inflammatory disease [J]. Am J Obstet Gynecol，2021，224（3）：251-257.
[2] Wiesenfeld HC，Meyn LA，Darville T，et al. A RandomizedControlled Trial of Ceftriaxone and Doxycycline，With or Without Metronidazole，for the Treatment of Acute Pelvic Inflammatory Disease [J]. Clin Infect Dis，2021，72（7）：1181-1189.
[3] Darville T. Pelvic Inflammatory Disease Due to Neisseria gonorrhoeae and Chlamydia trachomatis：Immune Evasion Mechanisms and Pathogenic DiseasePathways [J]. J Infect Dis，2021，224（12 Suppl 2）：S39-S46.
[4] Xu SX，Gray-Owen SD. Gonococcal Pelvic Inflammatory Disease：PlacingMechanistic Insights Into the Context of Clinical and EpidemiologicalObservations [J]. J Infect Dis，2021，224（12 Suppl 2）：S56-S63.
[5] Savaris RF，Fuhrich DG，Maissiat J，et al. Antibiotic therapy forpelvic inflammatory disease [J]. Cochrane Database Syst Rev，2020，8（8）：CD010285.
[6] Curry A，Williams T，Penny ML. Pelvic Inflammatory Disease：Diagnosis，Management，and Prevention [J]. Am Fam Physician，2019，100（6）：357-364.
[7] Siegenthaler F，Krause E，Mueller MD. Diagnostik und Therapie der Adnexitis（Pelvic Inflammatory Disease）[Management of Pelvic Inflammatory Disease] [J]. TherUmsch，2020，77（4）：164-170.
[8] 谢幸，苟文丽.妇产科学[M].8版.北京：人民卫生出版社，2013：89-91.
[9] 孙兵，车晓明.视觉模拟评分法（VAS）[J].中华神经外科杂志，2012，28（6）：1.
[10] 曹丽佳，孟强，于新路，等.三种治疗仪治疗慢性前列腺炎疗效比较[J].武警医学院学报，2010，19（10）：804-806.
[11] 孟强，曹丽佳，于新路，等.腔道介入治疗慢性前列腺炎的疗效评价-附500例报告[J].辽宁医学杂志，2010，24（6）：297-298.
[12] 何伟，孙自学，王光策.磁振磁电治疗仪联合前列倍喜胶囊治疗慢性前列腺炎/慢性骨盆疼痛综合征的临床疗效观察[J].中华男科学杂志，2020，26（5）：452-456.
[13] 罗文佳，王丽平，武婧，等.妇可靖胶囊对慢性盆腔炎大鼠炎症细胞因子、氧自由基水平的影响及相关机制研究[J].中医药导报，2020，26（10）：27-31.
[14] 于凤艳，颜新彦，霍叶琳.甲硝唑联合头孢曲松、多西环素治疗盆腔炎对细胞因子、免疫功能和血液流变学的影响[J].河北医药，2022，44（1）：72-75.
[15] 尉桂芳.丹芍汤灌肠联合氟罗沙星对慢性盆腔炎患者血清炎症细胞因子的影响[J].中国妇幼保健，2020，35（9）：1649-1652.
[16] 王艳青，李艳.妇乐片联合多西环素、头孢曲松对慢性盆腔炎患者GM-CSF、MCP-1水平的影响[J].检验医学与临床，2021，18（5）：687-689.
[17] 覃倩，张曼，尤剑鹏，等.瑶医水莲风亏方对盆腔炎性疾病后遗症大鼠IL-6、IL-8、VEGF及MMP-2表达的影响[J].中华中医药杂志，2021，36（6）：3598-3602.
[18] Levin G，Dior UP，Gilad R，et al. Pelvicinflammatory disease among users and non-users of an intrauterine device [J]. J Obstet Gynaecol，2021，41（1）：118-123.
[19] 王华斌.桂枝茯苓丸辅治慢性盆腔炎疗效及对血液流变学、氧化应激和血清hs-CRP、TGF-β1、GM-CSF、补体C3水平的影响[J].中华中医药学刊，2020，38（2）：214-217.
[20] 王艳，焦波，吉文倩，等.小金丸联合左氧氟沙星和甲硝唑对盆腔炎性包块患者的临床疗效[J].中成药，2020， 42（3）：644-647.
[21] 朱凤娣，田颖，钟剑飞，等.康妇炎胶囊治疗湿热蕴结型盆腔炎性疾病后遗症及对患者IL-2、TNF-α的影响研究[J].陕西中医，2020，41（8）：1095-1097.
[22] 霍志平，李红霞，王宏利，等.盆腔炎性疾病后遗症患者外周血miR-34a、SIRT1的表达及临床意义[J].临床和实验医学杂志，2022，21（5）：525-529.
[23] 马静，丁丽，王妍，等.丹白颗粒联合阿奇霉素治疗慢性盆腔炎的疗效分析[J].世界中医药，2020，15（16）：2430-2433.
[24] 王华斌.桂枝茯苓丸辅治慢性盆腔炎疗效及对血液流变学、氧化应激和血清hs-CRP、TGF-β1、GM-CSF、补体C3水平的影响[J].中华中医药学刊，2020，38（2）：214-217.
[25] 冯伟，马建文，吕瑞凰.中西医结合疗法治疗慢性盆腔炎的临床效果及对炎症相关因子和血液流变学的影响[J].中国医药导报，2017，14（24）：151-154.
[26] 刘敏，王小燕，贾瑞琳，等.当归芍药散优化方抗慢性盆腔炎的实验研究[J].中国医药导报，2021，18（3）：17-20.
[27] 朱姝，李淑萍，黄素英.桂枝茯苓丸合小柴胡汤化裁治疗盆腔炎性疾病后遗症临床疗效观察[J].中国医药科学，2021，11（23）：9-12，52.
[28] 李桂梅，刘冬梅，平伟，等.少腹逐瘀胶囊对慢性盆腔炎红细胞免疫功能的影响[J].医学综述，2016，22（19）：3893-3895.